BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Researchers looked at how the vaccine affected patients' corneas - the clear front part of the eye that allows light to come ...

According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, and the benefit-risk profile of the vaccine remains positive for all ...

Scientists in Turkey found that the Pfizer COVID-19 vaccine impacted some people's corneas, according to a study.

A Turkish study finds Pfizer’s COVID-19 vaccine may cause temporary changes in corneal thickness and cell count, raising concerns for those with existing eye issues or transplants.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

The FDA has updated its warnings about potential cardiac risks associated with Pfizer and Moderna COVID-19 vaccines, particularly focusing on young men. Discover essential information about the latest ...

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company delayed the results of COVID-19 vaccine trials to influence the 2020 election.

The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company delayed the results of COVID-19 vaccine trials to influence the 2020 election.

An FDA review states that the benefits of Pfizer’s COVID-19 vaccine in kids ages 5 to 11 outweigh the potential risks, The Washington Post reported. The FDA noted in its review, released Oct. 22 ...

In adults 18 years of age and older, Comirnaty Omicron XBB.1.5, Comirnaty JN.1 and Comirnaty KP.2 may be administered concomitantly with a pneumococcal conjugated vaccine (PCV). an unadjuvanted ...

Pfizer has faced headwinds post-COVID, but remains a key player with a robust R&D pipeline and an attractive 7.5%+ dividend yield. The pharmaceutical industry thrives on high R&D investment and ...